Receipt of gender-affirming care led to a reduced risk of depression and suicidality among transgender and non-binary (TNB) youth, according to a prospective study presented at the American Academy of Pediatrics 2021 National Conference & Exhibition (AAP 2021).
Switching to tenofovir alafenamide (TAF) from nucleos(t)ide analogue therapies was associated with improved virologic response and liver function in patients with chronic hepatitis B virus (HBV) infection, even in those with decompensated HBV cirrhosis, according to real-world studies presented at AASLD 2021.
A recent study involving Dutch teenagers has found that a higher number of episodes of >20 minutes of continuous smartphone use may lead to more myopic refractive errors. Such association does not exist in those with high outdoor exposure.
The pan-PPAR* agonist lanifibranor further advances into the NASH** treatment field, as more data from the phase IIb NATIVE*** study presented at AASLD 2021 unveil further histologic and therapeutic benefits for patients with NASH.
Several older adults in Singapore have low appendicular skeletal muscle mass index (ASMI), particularly those who are at high risk for malnutrition, according to a recent study. Smoking, drinking, and low bone mass are other warning signs of low ASMI.
Medical Protection Society (MPS) has received numerous requests for advice on the risks involved in remote consulting, or telemedicine, since the start of the COVID-19 pandemic. It is important that you are aware of and protect yourself against the medicolegal pitfalls. Dr Sara Sreih and Dr Uzair Sidek, medicolegal consultants of MPS, answer frequently asked questions on safety during remote consulting.
New drug applications approved by US FDA as of 16-30 November 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Empagliflozin provides a significant clinical benefit within 90 days and shows no safety concerns in patients hospitalized for acute heart failure (HF), according to results of the EMPULSE trial reported at the American Heart Association (AHA) Scientific Sessions 2021.
The SGLT2i* canagliflozin significantly improves symptoms and quality of life (QoL) early on during treatment in people with heart failure (HF) due to either reduced or preserved ejection fraction (rEF or pEF), regardless of whether they have type 2 diabetes (T2D), according to the CHIEF-HF** study presented at AHA 2021.